Tumor characteristics including HR-/HER2 + receptor status (OR 0.95, 95% CI: 0.92–0.98) and triple negative receptor status (OR 0.94, 95% CI: 0.92–0.95) had lower odds of FC. The gene discussed is ERBB2; the disease is neoplasm.